Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.
about
Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate bindingHint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferasesReduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer.Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells.The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.Hits, Fhits and Nits: beyond enzymatic function.FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells.Alteration of the fragile histidine triad gene early in carcinogenesis: an update.Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells.Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.The expression of FHIT, PCNA and EGFR in benign and malignant breast lesionsFragile histidine triad gene alterations are not essential for hepatocellular carcinoma development in South Korea.Fhit tumor suppressor: guardian of the preneoplastic genome.Nit1 and Fhit tumor suppressor activities are additive.HIV-TAT-fused FHIT protein functions as a potential pro-apoptotic molecule in hepatocellular carcinoma cells.Fhit regulates invasion of lung tumor cells.Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR.The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression.Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer.Concordant loss of fragile gene expression early in breast cancer development.
P2860
Q24550737-76D88BB4-BF01-4DF1-B26A-6486AD611597Q24649493-C64D7564-0C9F-4F5F-AA72-A88E99235311Q30543686-AEC1F324-0E26-46FA-9A1C-96912D8381C4Q33761959-3DB64731-9620-49CD-8725-76053C58F69FQ34208784-F48636C9-2462-4B89-A4A4-3339628C8FA6Q34586553-2EB70D68-BE2C-437D-84F4-6BE53D12F834Q35191084-60550C18-1CB2-4658-A241-6FA620AF8D0FQ35608979-F90A57BD-C2A7-4055-B4F5-7BAF7C2D9761Q35916207-6B74F9AE-7C0B-4927-A49C-951AD19BA092Q36446169-BD034C73-870D-4FE0-9DB1-A22314A90DDCQ36610527-A964D7BF-EDB6-422E-9681-AA486AEFF4A5Q37277440-71D12DA0-1A1B-48F4-9484-76F2F05B3DC8Q37352008-2C557A62-9E50-47BC-B21E-3FAF024FAF90Q37389231-2E5F9CAC-C5D1-44EC-AF45-7B899427F6ECQ39523456-0773658B-669D-4A39-9D47-0105DDCFC778Q39771185-689DCD5D-0178-4EFA-95D6-2CE23B54ABEDQ40339478-9D0ABBFD-ABE3-4E71-92DF-5F8B512CC1FCQ40368333-64F3851E-336A-4613-80C8-4EDBCB0920BFQ40503168-C26CC585-5832-4E0B-9673-2C112B24460DQ44623571-83FD3453-337F-44FF-BAB4-843572438B51Q46584560-F9FC80DF-66A2-469D-AF5E-60144AD2E1C5
P2860
Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Potential cancer therapy with ...... ew of the preclinical studies.
@ast
Potential cancer therapy with ...... ew of the preclinical studies.
@en
Potential cancer therapy with ...... ew of the preclinical studies.
@nl
type
label
Potential cancer therapy with ...... ew of the preclinical studies.
@ast
Potential cancer therapy with ...... ew of the preclinical studies.
@en
Potential cancer therapy with ...... ew of the preclinical studies.
@nl
prefLabel
Potential cancer therapy with ...... ew of the preclinical studies.
@ast
Potential cancer therapy with ...... ew of the preclinical studies.
@en
Potential cancer therapy with ...... ew of the preclinical studies.
@nl
P2093
P356
P1476
Potential cancer therapy with ...... ew of the preclinical studies.
@en
P2093
P304
P356
10.1001/JAMA.286.19.2441
P407
P577
2001-11-01T00:00:00Z